Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Increase in Short Interest

Kazia Therapeutics Limited (NASDAQ:KZIA) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 259,500 shares, an increase of 6.9% from the March 15th total of 242,800 shares. Based on an average daily volume of 838,400 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of Kazia Therapeutics

A number of large investors have recently bought and sold shares of the stock. Armistice Capital LLC bought a new stake in Kazia Therapeutics in the fourth quarter valued at $1,088,000. Platinum Investment Management Ltd. bought a new stake in Kazia Therapeutics in the fourth quarter valued at $801,000. Morgan Stanley grew its position in Kazia Therapeutics by 25.9% in the fourth quarter. Morgan Stanley now owns 257,341 shares of the company’s stock valued at $158,000 after acquiring an additional 52,891 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in Kazia Therapeutics in the fourth quarter valued at $45,000. 30.89% of the stock is currently owned by institutional investors.

Kazia Therapeutics Stock Performance

KZIA opened at $0.31 on Tuesday. Kazia Therapeutics has a 1 year low of $0.19 and a 1 year high of $1.68. The stock’s 50 day simple moving average is $0.29 and its 200-day simple moving average is $0.45.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.